Amphastar P (AMPH) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.

Total Cash From Operating Activities Chart for Amphastar P

Amphastar P (AMPH) operating cash flow for FY2025 was USD 156.1M, a -26.8% change from FY2024. Amphastar P's operating cash flow grew from USD 19.1M in 2011 to USD 156.1M in 2025 (717.5% over 14 years). Operating cash flow compound annual growth rate: 5-year CAGR of 22.2%, 10-year CAGR of 30.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.07B
Implied Share Price
$25.14
Enterprise Value
$1.66B
Revenue (TTM)
$730.02M
EBITDA
$194.51M
Profit Margin
10.76%
Trailing P/E
14.88
Forward P/E
0.00
Price/Book (MRQ)
1.63
Price/Sales (TTM)
1.46
EV/EBITDA
6.68
EV/Revenue
2.29
Dividend Yield
—
Book Value
$18.06
Free Cash Flow (FY2025)
$121.23M
Free Cash Flow Yield
11.34%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.